Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk

American Journal of Physiology - Endocrinology and Metabolism

Volumn 284, Issue 6 47-6, 2003, Pages

  Herbst, Karen L ^a,b   Amory, John K ^a   Brunzell, John D ^a   Chansky, Howard A ^a   Bremner, William J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Androgen; Lipoprotein particle density

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TESTOSTERONE ENANTATE;

AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; DOUBLE BLIND PROCEDURE; ENZYME ACTIVITY; HIP SURGERY; HORMONE ACTION; HUMAN; KNEE SURGERY; MALE; OBESITY; PARTICLE SIZE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0037840433     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00524.2002     Document Type: Article

References (42)

1. Amory JK, Chansky HA, Chansky KL, Camuso M, Hoey C, Anawalt BD, Matsumoto AM, and Bremner WJ. Pre-operative supraphysiological testosterone administration in older men undergoing knee replacement surgery. J Am Geriatr Soc 50: 1698-1701, 2002.
2. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, and Krauss RM. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260: 1917-1921, 1988.
3. Austin MA, King MC, Vranizan MA, and Kraus RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 82: 495-506, 1990.
4. Auwerx JH, Marzetta CA, Hokanson JE, and Brunzell JD. Large buoyant LDL-like particles in hepatic lipase deficiency. Arteriosclerosis 9: 319-325, 1989.
5. Bachorik PS and Albers JJ. Precipitation methods for quantification of lipoproteins. In: Methods in Enzymology, edited by Albers JJ and Segrest JP. Orlando, FL: Academic, 1986, p. 78-100.
6. Bagatell CJ and Bremner WJ. Androgen and progestagen effects on plasma lipids. Prog Cardiovasc Dis 38: 255-271, 1995.
7. Bagatell CJ, Heiman JR, Matsumoto A, Rivier JE, and Bremner WJ. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J Clin Endocrinol Metab 79: 561-567, 1994.
8. Bagatell CJ, Knopp RH, Vale WW, Rivier JE, and Bremner WJ. Physiologic levels of testosterone suppress HDL cholesterol levels in normal men. Ann Intern Med 116: 967-973, 1992.
9. Berg G, Schreier L, Geloso G, Otero P, Nagelberg A, and Levalle O. Impact on lipoprotein profile of long-term testosterone replacement in hypogonadal men. Horm Metab Res 34: 87-92, 2002.
10. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, and Storer TW. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 281: E1172-E1181, 2001.
11. Carr MC, Hokanson JE, Deeb SS, Purnell JQ, Mitchell ES, and Brunzell JD. A hepatic lipase gene promoter polymorphism attenuates the increase in hepatic lipase activity with increasing intra-abdominal fat in women. Arterioscler Thromb Vasc Biol 19: 2701-2707, 1999.
12. Carr MC, Hokanson JE, Zambon A, Deeb SS, Barrett PH, Purnell JQ, and Brunzell JD. The contribution of intraabdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity. J Clin Endocrinol Metab 86: 2831-2837, 2001.
13. Chung BH, Wilkinson T, Geer JC, and Segrest JP. Preparative and quantitative isolation of plasma lipoproteins: rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor. J Lipid Res 21: 284-291, 1980.
14. Franceschini G. Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease. Am J Cardiol 88: 9N-13N, 2001.
15. Friedewald WT, Levy RI, and Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 18: 499-502, 1972.
16. Giri S, Thompson PD, Taxel P, Contois JH, Otvos J, Allen R, Ens G, Wu AHB, and Waters DD. Oral estrogen improves serum lipids, homocysteine and fibrinolysis in elderly men. Atherosclerosis 137: 359-366, 1998.
17. Goldberg RB, Rabin D, Alexander AN, Doelle GC, and Getz GS. Suppression of plasma testosterone leads to an increase in serum total and high density lipoprotein cholesterol and apoproteins A-I and B. J Clin Endocrinol Metab 60: 203-207, 1984.
18. Griffin BA, Furlonger N, and Iversen A. Plasma apolipoprotein(b) to LDL cholesterol ratio as a marker of small, dense LDL. Ann Clin Biochem 37: 537-539, 2000.
19. Haffner SM, Laakso M, Miettinen H, Mykkanen L, Karhapaa P, and Rainwater DL. Low levels of sex hormone-binding globulin and testosterone are associated with smaller, denser low density lipoprotein in normoglycemic men. J Clin Endocrinol Metab 81: 3697-3701, 1996.
20. Hokanson J, Austin M, and Brunzell J. Measurement and clinical significance of low-density lipoprotein subclasses. In: Handbook of Lipoprotein Testing, edited by Rifai N, Warnick G, and Dominiczak M. Washington, DC: AACC, 1997, p. 267-282.
21. Iverius P and Brunzell J. Human adipose tissue lipoprotein lipase: changes with feeding in relation to postheparin plasma enzyme. Am J Physiol Endocrinol Metab 249: E107-E114, 1985.
22. Kantor MA, Bianchini A, Bernier D, Sady SP, and Thompson PD. Androgens reduce HDL2-cholesterol and increase hepatic triglyceride lipase activity. Med Sci Sports Exerc 17: 462-465, 1985.
23. Kinnunen PKJ, Virtanen JA, and Vainio P. Lipoprotein lipase and hepatic endothelial lipase: their roles in plasma lipoprotein metabolism. Atherosclerosis Rev 11: 65-105, 1983.
24. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenaise GR, Lupien PJ, and Despres JP. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation 95: 69-75, 1997.
25. Meriggiola MC, Marcovina S, Paulsen CA, and Bremner WJ. Testosterone enanthate at a dose of 200 mg/week decreases HDL-cholesterol levels in healthy men. Int J Androl 18: 237-242, 1995.
26. Miller NE. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 113: 589-597, 1987.
27. Ozata M, Yildirimkaya M, Bulur M, Yilmaz K, Bolu E, Corakci A, and Gundogan MA. Effects of gonadotropin and testosterone treatments on lipoprotein(a), high density lipoprotein particles, and other lipoprotein levels in male hypogonadism. J Clin Endocrinol Metab 81: 3372-3378, 1996.
28. Purnell JQ, Marcovina SM, Hokanson JE, Kennedy H, Cleary PA, Steffes MW, and Brunzell JD. Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial. Diabetes 44: 1218-1226, 1995.
29. Singh AB, Hsia S, Alaupovic P, Sinha-Hikim I, Woodhouse L, Buchanan TA, Shen R, Bross R, Berman N, and Bhasin S. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and c-reactive protein in healthy young men. J Clin Endocrinol Metab 87: 136-143, 2002.
30. Sorva R, Kuusi T, Taskinen M-R, Perheentupa J, and Nikkila EA. Testosterone substitution increases the activity of lipoprotein lipase and hepatic lipase in hypogonadal males. Atherosclerosis 69: 191-197, 1988.
31. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, and Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 276: 882-888, 1996.
32. Tan KCB, Shiu SWM, and Kung AWC. Alterations in hepatic lipase and lipoprotein subfractions with transdermal testosterone replacement therapy. Clin Endocrinol (Oxf) 51: 765-769, 1999.
33. Tan KCB, Shiu SWM, Pang RWC, and Kung AWC. Effects of testosterone replacement on HDL subfractions and apolipoprotein A-I containing lipoproteins. Clin Endocrinol (Oxf) 48: 187-194, 1998.
34. Thompson PD, Cullinane EM, Sady SP, Chenevert C, Saritelli AL, and Herbert PN. Contrasting effects of testosterone and stanozolol on serum lipoproteins. JAMA 261: 1165-1168, 1989.
35. Vermuelen A. Commentary to the article - low levels of sex hormone-binding globulin and testosterone are associated with smaller, denser low density lipoprotein in normoglycemic men. J Clin Endocrinol Metab 83: 1822-1823, 1998.
36. Von Eckardstein A, Kliesch S, Nieschlag E, Chirazi A, Assman G, and Behre HM. Suppression of endogenous testosterone in young men increases serum levels of high density lipoprotein subclass lipoprotein A-I and lipoprotein (a). J Clin Endocrinol Metab 82: 3367-3372, 1997.
37. Warnick GR. Enzymatic methods for quantitation of lipoprotein lipids. Methods Enzymol 129: 101-123, 1986,
38. Warnick GR, Benderson J, and Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantification of high-density lipoprotein cholesterol. Clin Chem 28: 1279-1288, 1982,
39. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, and Siscovick DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med 111: 261-269, 2001.
40. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333, 2002.
41. Zambon A, Austin MA, Brown BG, Hokanson JE, and Brunzell JD. Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. Arterioscler Thromb 13: 147-153, 1993.
42. Zgliczynski S, Ossowski M, Slowinska-Srzednicka J, Brzezinska A, Zgliczynski W, Soszynski P, Chotkowska E, Srzednicki M, and Sadowski Z. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis 121: 35-43, 1996.